Cybin announces scientific management transition following achievement of final adelia milestones

Toronto--(business wire)--cybin inc. (neo:cybn) (nyse american:cybn) (“cybin” or the “company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, today announced changes to its scientific management team. following the achievement of the final milestones as contemplated by the terms of a contribution agreement dated december 4, 2020 between cybin and adelia therapeutics inc. (“adelia”).
CYBN Ratings Summary
CYBN Quant Ranking